TOI - NASDAQ

The Oncology Institute, Inc.

TOI·NASDAQ

$4.59

-7.8%

HealthcareMedical - Care Facilities

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$458.92M

EPS-0.5400

P/E Ratio-54.27

Earnings Date08/12/2026

164.66M

Assets

-5%

3Y-37.0%

5Y+151.0%

10Y+177.0%

180.38M

Total Liabilities

3Y+30.0%

5Y+380.0%

10Y+943.0%

-15.72M

Total Equity

-538%

3Y-113.0%

5Y-156.0%

10Y-137.0%

The Oncology Institute, Inc. Funding & Solvency Profile

TOI · NASDAQ

Current Assets

Cash & Cash Equivalents33.56M

Net Receivables59.32M

Inventory16.88M

Other Current Assets2.99M

Total Current Assets113 M

Non-Current Assets

Property, Plant & Equipment33.06M

Goodwill & Intangible Assets18.25M

Long-Term Investments0.00

Other Non-Current Assets606.00K

Total Non-Current Assets34 M

Total Assets

164.66M

Financial Health Analysis

Current Ratio

1.59x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Working Capital

42 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

68% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

The Oncology Institute, Inc. Balance Sheet

TOI • NASDAQ

The Oncology Institute, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	33.6M	49.7M	33.5M	14M	114.3M	6M	2.4M
Short-Term Investments	0.0	0.0	49.4M	59.8M	0.0	0.0	0.0
Cash & Short-Term Investments	33.6M	49.7M	82.9M	73.8M	114.3M	6M	2.4M
Net Receivables	59.3M	48.7M	42.9M	40.4M	21.2M	17.3M	14.7M
Accounts Receivables	59M	48.3M	42.4M	39.8M	20M	17.1M	14.6M
Other Receivables	322K	346K	551K	617K	1.2M	113K	118.2K
Inventory	16.9M	10M	13.7M	9.3M	6.4M	4.4M	3.9M
Prepaids	0.0	0.0	4M	6.9M	11.2M	2.1M	723.1K
Other Current Assets	3M	4M	0.0	0.0	875K	0.0	0.0
Total Current Assets	112.7M	112.4M	143.5M	130.4M	154.1M	29.7M	21.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	33.1M	37.7M	40.1M	33M	4.2M	2.1M	1.6M
Goodwill	7.2M	7.2M	7.2M	21.4M	26.6M	14.2M	14.1M
Intangible Assets	11M	14.8M	17.9M	18M	18.2M	19.5M	22M
Goodwill & Intangible Assets	18.2M	22M	25.1M	39.4M	44.9M	33.7M	36.1M
Long-Term Investments	0.0	0.0	0.0	58.4M	-371K	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	371K	0.0	0.0
Other Non-Current Assets	606K	589K	561K	477K	320K	122K	97.9K
Total Non-Current Assets	51.9M	60.3M	65.7M	131.2M	49.4M	36M	37.7M
Total Assets	164.7M	172.7M	209.2M	261.7M	203.4M	65.7M	59.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	43.2M	24.3M	14.4M	9.6M	15.6M	13.8M	9.4M
Accounts Payable	43.2M	24.3M	14.4M	9.4M	15.6M	12.6M	8.9M
Other Payables	0.0	0.0	0.0	255K	0.0	1.1M	488.7K
Accrued Expenses	0.0	6M	2.1M	4.1M	3.3M	9.5M	1.5M
Short Term Debt	7.2M	0.0	0.0	0.0	183K	5.4M	0.0
Capital Lease Obligations (Current)	0.0	6.8M	6.4M	5.5M	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	255K	132K	1.1M	488.7K
Deferred Revenue	0.0	4.7M	545K	1.1M	592K	3.4M	0.0
Other Current Liabilities	20.6M	10.4M	11.3M	9.3M	10.1M	-3.4M	2.7M
Total Current Liabilities	71M	52.2M	34.8M	29.7M	29.8M	28.6M	13.6M
NON-CURRENT LIABILITIES
Long Term Debt	77.4M	93.1M	86.8M	80.6M	0.0	6.6M	0.0
Deferred Tax Liabilities (Non-Current)	7.8M	32K	32K	108K	371K	1.6M	3M
Other Non-Current Liabilities	12.9M	527K	4.1M	6M	69.1M	807K	0.0
Total Non-Current Liabilities	117.2M	116.9M	117.4M	108.8M	69.5M	9M	3.7M
Capital Lease Obligations	19.1M	30M	32.8M	27.6M	0.0	0.0	0.0
Total Liabilities	180.4M	169.1M	152.2M	138.5M	99.3M	37.6M	17.3M
SHAREHOLDERS' EQUITY
Treasury Stock	-1M	-1M	-1M	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	80.1M	48.1M
Common Stock	10K	8K	8K	7K	7K	6K	575.0
Additional Paid-In Capital	256.7M	215.4M	204.2M	186.3M	167.4M	80.4M	94K
Retained Earnings	-271.4M	-210.8M	-146.2M	-63.1M	-63.2M	-52.3M	-6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	-575.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	-80.1M	0.0
Total Stockholders' Equity	-15.7M	3.6M	57M	123.2M	104.2M	28.1M	42.2M
Total Equity	-15.7M	3.6M	57M	123.2M	104.2M	28.1M	42.2M
SUMMARY
Total Liabilities & Equity	164.7M	172.7M	209.2M	261.7M	203.4M	65.7M	59.5M
Total Investments	0.0	0.0	49.4M	118.2M	-371K	0.0	0.0
Total Debt	103.7M	123.2M	119.7M	108.2M	183K	11.9M	0.0
Net Debt	70.1M	73.5M	86.2M	94.2M	-114.1M	5.9M	-2.4M
Shares Outstanding	93,493,827	93,493,827	93,493,827	93,493,827	93,493,827	93,493,827	93,493,827

SEC Filings

TOI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 13, 2026	March 13, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 02, 2026	2026	View Filing

Showing 1 to 10 of 128 filings

Related Guides

Blog Categories

Continue your TOI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.